State of the Science Summit on GI Malignancies | Conference

Dr. Oberstein on PEGPH20 in Patients With Pancreatic Cancer

May 3rd 2018

Paul E. Oberstein, MD, assistant professor of medicine, assistant director, Pancreatic Cancer Center, director, Gastrointestinal Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the use of PEGPH20 in advanced pancreatic cancer.

Dr. Beatty on the Potential for Immunotherapy in GI Malignancies

May 2nd 2018

Gregory L. Beatty, MD, PhD, assistant professor of medicine, director of Tanslation Research, Pancreatic Cancer Research Center, University of Pennsylvania Perelman School of Medicine, discusses the potential for immunotherapy in gastrointestinal malignancies.

Dr. Welling on SIRT in Patients With Hepatobiliary Neoplasms

May 1st 2018

Theodore H. Welling MD, associate professor, department of Surgery, director, Liver Tumor Program, NYU Langone’s Perlmutter Cancer Center, discusses the use of selective internal radiation therapy (SIRT) in patients with hepatobiliary cancers.

Dr. Simeone on Emerging Subtypes of Pancreatic Cancer

May 1st 2018

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses emerging subtypes of pancreatic cancer.

Precision Medicine Impact Grows in GI Cancer Paradigm

March 30th 2018

Bert H. O’Neil, MD, discusses the role of molecular testing throughout GI cancers and highlights the current and developing treatment landscape for patients with colorectal cancer.

Immunotherapy Arrives in Gastric Cancer

March 30th 2018

Manish A. Shah, MD, discusses the advancements being made in the treatment of patients with advanced gastric and gastroesophageal junction cancer.

Expert Sheds Light on Recent Advances in mCRC

March 29th 2018

Shubham Pant, MD, shares his insight on the future direction of the treatment landscape of colorectal cancer.

Dr. O'Neil Discusses the Current Treatment of Patients With CRC

March 28th 2018

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the current treatment of patients with colorectal cancer.

Dr. Pant on the Future of mCRC Treatment

March 28th 2018

Shubham Pant, MD, associate medical director of the Clinical & Translational Research Center, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing efforts in metastatic colorectal cancer (mCRC) and his hope for the future treatment landscape.

Dr. Helft on the CAPTEM Regimen in Patients With Neuroendocrine Tumors

March 27th 2018

Paul R. Helft, MD, professor of medicine, Indiana University School of Medicine, Indiana University Health Melvin and Bren Simon Cancer Center, discusses the use of capecitabine and temozolomide across gastrointestinal (GI) neuroendocrine tumors.

Dr. Larson on Ongoing Trials in Colorectal Cancer

November 9th 2017

Tim G. Larson, MD, oncologist, Minnesota Oncology, discusses ongoing trials in colorectal cancer (CRC).

Expert Discusses Continued Growth of Immunotherapy in Gastric/GEJ Cancer

October 6th 2017

Harry H. Yoon, MD discussed the promise of immunotherapy and emphasized the importance of mismatch repair deficiency testing in gastric/GEJ Cancer.

Expert Discusses Ongoing Advances With Immunotherapy in CRC

September 28th 2017

Tanios Bekaii-Saab, MD, discusses the emerging role of immunotherapy in patients with MSI-H colorectal cancer.

PEGPH20 Could Alter Frontline Treatment in Pancreatic Cancer

September 27th 2017

Optimizing frontline therapy for patients with pancreatic cancer is an ongoing focal point in the field.

Dr. Alberts Discusses Updates in Liver Cancer

September 26th 2017

Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses recent updates in liver cancer.

Grothey Highlights Biomarker Research in CRC

September 26th 2017

Axel Grothey, MD, discusses current first-line treatments for patients with CRC and the importance of developing biomarkers for this population.

Therapies in Development to Improve Outcomes in BRAF-Mutated CRC

September 26th 2017

Tim G. Larson, MD, discusses emerging data involving immunotherapy for patients with microsatellite instability (MSI)/microsatellite stable (MSS) colorectal cancer (CRC) and highlighted some of the identified molecular mutations in patients with CRC

Dr. Larson on Immunotherapy for Colorectal Cancer

September 26th 2017

Tim G. Larson, MD, Minnesota Oncology discusses the development of immunotherapy for patients with colorectal cancer (CRC).

Dr. Yoon on Immunotherapy in Gastric Cancer

September 25th 2017

Harry H. Yoon, MD, associate professor of oncology, Mayo Clinic, discusses the benefits demonstrated with nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with gastric cancer.

Dr. Saab on Immunotherapy in MSI-H GI Malignancies

September 23rd 2017

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses immunotherapy in a patient with microsatellite instability-high (MSI-H) gastrointestinal malignancies.